One Health in Action…


One Health Initiative team *Physician member Joins Prominent International veterinary biopharmaceutical company

ANNOUNCEMENT: Dr. Thomas Monath (Harvard School of Public Health) joins SmartVet Advisory Board and heads up Transdermal Vaccine Project.

SmartVet is glad to formally announce that Dr. Thomas Monath, Adjunct Professor Harvard School of Public Health, has now joined the SmartVet team. Dr Monath will oversee SmartVet's Transdermal Vaccine Project and help direct research efforts toward the most efficient way of achieving successful transdermal immunization using a similar variation of the existing VetGun Delivery System.

Dr. Thomas P. Monath [] is a physician and Adjunct Professor (Emeritus), Harvard School of Public Health. He has substantial bioscience investment experience as an ex-partner in the Pandemic and Biodefense Fund, Kleiner Perkins Caufield & Byers.

Tom’s direct industry experience includes 14 years as Chief Scientific Officer and Executive Director of Acambis (a publicly traded biopharmaceutical company which was acquired by Sanofi-Aventis in 2008). While at Acambis he pioneered and directed Research and Development of ChimeriVax® vaccines against dengue, Japanese encephalitis, West Nile, as well as vaccines against yellow fever, Clostridium difficile and ACAM2000, a smallpox vaccine that has now replaced calf lymph vaccine in the national stockpile for defense against bioterrorism. He served in the uniformed services of the U.S. Army and U.S. Public Health Service for 24 years prior to retiring in 1992 as a Colonel. Between 1973-1988, Tom was Director, Division of Vector-Borne Viral Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado and from 1989-92 was Chief of the Virology Division, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). He has worked in Nigeria, Sierra Leone, Cameroon, Argentina and Ecuador doing field research on arboviruses and hemorrhagic fevers. He is on the editorial board of ten scientific journals and has published approximately 385 papers and edited six books on the epidemiology, immunology and pathogenesis of viruses and on vaccine development. Tom received the Nathanial A. Young Award (1984), the Richard M. Taylor Award (1996), and the Walter Reed Medal (2002) from the American Society of Tropical Medicine & Hygiene (ASTMH) and was President of American Society of Tropical Medicine & Hygiene from 2004-2005. He has served on numerous government and international committees on infectious diseases, biosecurity, World Health Organization (WHO) expert committees and the National Vaccines Advisory Committee (USA). Between 1998 and 2000, he was Senior Science Advisor to the Director, Central Intelligence Agency. A leader in the “One Health” movement, Tom served on the American Veterinary Medical Association’s (AVMA) “One Health” Task Force and subsequently the One Health Commission (USA). Tom received his undergraduate degree from Harvard College and an M.D. from Harvard Medical School. He trained in internal medicine at the Peter Bent Brigham Hospital in Boston, MA.

For more details on the SmartVet Executive Team, and it's Advisory Board, please click here. For further information regarding SmartVet's Transdermal Vaccine Project, please contact Grant Weyer, CEO at


*Important Note:  Dr. Monath published a visionary, landmark One Health Vaccine Journal article in September 2013 (see below)…and having an eminent physician virologist/vaccinologist working with a veterinary company utilizes the One Health approach for potentially expeditious/advanced discoveries and applications of new technologies for animal and human health.


Posted Wednesday, October 09, 2013 on One Health Initiative website NEWS page:

A potential large scale “One Health in Action” ... another dynamic case for implementing One Health!


Vaccines against diseases transmitted from animals to humans: A one health paradigm

“This review focuses on the immunization of animals as a means of preventing human diseases (zoonoses). …”

In simple terms, the idea is to develop vaccines that protect domestic animals and wildlife thereby establishing effective barriers against human infections.  Developing animal vaccines are less expensive and are less strictly regulated than are those for humans.  Hopefully a common sense One Health approach can go forward.,%20MD%20Sept%202013%20One%20Health%20Vaccine%20Article.pdf